WASHINGTON—Health insurers confirmed this week that prescription formularies are built using a disciplined, data-driven method known internally as “Who Brought the Biggest Rebate.” Executives described the process as neutral, objective, and very spreadsheet-forward. Patient impact was acknowledged as a downstream consideration.
A pharmacy benefits executive said patients always come first. He clarified that they come first in line to receive whichever drug best supports quarterly performance. He closed a laptop. A tab labeled Rebates_Final_v7_DO_NOT_SHARE disappeared.
Formulary placement is determined after prescriptions are written and filled. Clinical value is reviewed briefly. Safety is assumed. Effectiveness is discussed in theory. Rebate size is entered into a column. The column sorts itself.
Executives said the system is often misunderstood. Preferred does not mean preferred for patients. It means preferred by accounting. Sometimes legal. Occasionally marketing. The word “preferred” tested well in focus groups.
Doctors submit prescriptions based on training, experience, and the patient in front of them. The formulary reviews that choice later. It has opinions. Those opinions arrive by fax.
A patient learns that the drug their doctor chose is non-preferred. The alternative is similar. Almost the same. Costs more. Requires three prior authorizations and a phone call that ends abruptly. The patient is told the system encourages choice.
One patient with a chronic condition said Drug A worked. Drug B caused side effects. Drug B also triggered a rebate. The patient learned to manage symptoms and expectations. Expectations adjusted faster.
Insurers said rebates reduce costs across the system. They did not define system. They did not define reduce. They confirmed savings exist. Somewhere. Not on bills. Not at the pharmacy. Not at the counter where the card is swiped.
A spokesperson said rebates are passed along. The phrasing was intentional. Passed along implies movement. It does not imply arrival.
Doctors described the formulary process as educational. They learn which drugs are aspirational. They learn which ones are realistic. They learn to write notes for machines. They learn new fax numbers.
One physician said the system is helpful. It removes the burden of clinical judgment. A spreadsheet handles that now. The spreadsheet does not ask questions.
Patients call insurers. Insurers suggest talking to doctors. Doctors submit appeals. Appeals are reviewed. Sometimes by people. Sometimes by rules. The outcome feels familiar.
Executives emphasized that formularies protect patients from unnecessary spending. The definition of unnecessary remains flexible. Drugs that work too well raise concerns.
Internal documents show drugs ranked by rebate size. The list is clean. Easy to read. No patient names appear.
Insurers said future updates will simplify the process further. Clinical review may be streamlined. Sorting may happen earlier. Decisions may happen faster.
The goal is efficiency. Patient-centered efficiency. The rebate column already knows what to do.
